




Pradaxa[®], the first and only NOAC with a specific reversal agent



For the reduction of the risk of stroke & systemic embolism in patients with non-valvular atrial fibrillation (SPAF)²

REFERENCES

1. Chokev K, Pokora J, et al. (2015). Idarucizumab for dabigatran reversal. *N Engl J Med* 2015;373:511-20.
2. Pradaxa[®] Prescribing Information, Boehringer.



Scan QR Code to access PRADAXA[®] & PRAXBIND[®] latest prescribing information

For healthcare professionals only.



Boehringer Ingelheim (Malaysia) Sdn. Bhd.
Incorporated in Malaysia
Sulhi 15-5 Level 15, Wisma USA Damansara 15, No 4 Jalan Changkat Semantan,
Damansara Heights, 50490 Kuala Lumpur.
Tel: +603 2092 0088 Fax: +603 2095 2818

Pradaxa[®]
dabigatran etexilate

Praxbind[®]
idarucizumab

Closing the Circle